Can Kratom Help With Opiate Withdrawal? Reviewing the Evidence

IMPORTANT DISCLAIMER: This article is an educational review of scientific research only. Kratom is not approved by the FDA to treat, cure, mitigate, or prevent opioid use disorder, opioid withdrawal, or any other medical condition. Nothing in this article constitutes medical advice or a recommendation to use kratom in place of evidence-based addiction treatment. Opioid use disorder is a serious medical condition. If you or someone you know is struggling with opioid dependence or withdrawal, please seek care from a licensed healthcare professional or contact SAMHSA's National Helpline at 1-800-662-4357 (free, confidential, 24/7).

 

 

Opioid use disorder (OUD) is one of the most devastating public health crises in modern American history. The CDC estimates that opioid overdoses claimed over 80,000 lives in the United States in 2021 alone. Against this backdrop, millions of people have sought alternatives to conventional addiction treatment — and kratom has emerged as one of the most widely discussed.

User communities, harm reduction advocates, and a growing number of researchers have raised questions about whether kratom — a botanical with partial mu-opioid receptor activity — might have a role in supporting opioid withdrawal management. This is a legitimate scientific question that deserves an honest, evidence-based answer. This guide fromPureCraft CBD reviews what the research has actually explored, what the findings suggest, and — critically — what responsible use of that evidence requires.

We begin with the most important statement in this article:kratom is not FDA-approved to treat opioid withdrawal or opioid use disorder. No kratom product should be used as a substitute for evidence-based addiction treatment without medical supervision. With that established, here is what the science says.

 

Understanding Opioid Withdrawal

Before examining kratom's relationship to opioid withdrawal, it is useful to understand what opioid withdrawal actually involves and why it drives continued opioid use.

When someone uses opioids regularly, their nervous system adapts to the presence of the drug — a process called neuroadaptation. Opioid receptors downregulate, and the brain's natural endorphin production decreases. When opioid use stops abruptly, the nervous system swings into a hyperactivated state, producing the withdrawal syndrome:

While opioid withdrawal is rarely life-threatening in otherwise healthy adults, it is intensely uncomfortable — and the fear of withdrawal is a major driver of continued opioid use and relapse. Managing withdrawal symptoms effectively is therefore a critical component of opioid use disorder treatment.

 

FDA-Approved Treatments for Opioid Withdrawal

Several FDA-approved medications exist specifically for opioid withdrawal and opioid use disorder. Understanding these is essential context before evaluating any alternative approach:

These treatments have robust clinical trial evidence and regulatory approval. The question the research has begun to explore is whether kratom occupies any complementary or harm-reduction role in this landscape — not whether it replaces these approaches.

 

Why Kratom Has Attracted Research Interest

Kratom's primary active alkaloids — mitragynine and 7-hydroxymitragynine — are partial agonists at mu-opioid receptors. This is the same receptor system targeted by methadone and buprenorphine, and the same system that opioids hijack to produce their effects and withdrawal syndrome.

Several observations drove initial research interest:

 

What the Research Has Explored

Large-Scale User Surveys

The most frequently cited evidence base comes from large-scale surveys of kratom users. A landmark 2017 study by Grundmann published inDrug and Alcohol Dependence surveyed 8,049 kratom users in the United States. Among the key findings:

Survey data of this kind is informative but carries significant limitations: it is self-reported, cannot establish causation, is subject to recall bias, and does not include medical verification of opioid use disorder diagnoses or withdrawal symptom severity.

Swogger and Walsh's Systematic Review (2018)

A systematic review published inDrug and Alcohol Dependenceby Swogger and Walsh (2018) examined the available literature on kratom use and health outcomes. Among their findings relevant to opioid withdrawal:

The authors noted that these findings warranted further investigation while acknowledging the limitations of predominantly self-report data. They called for controlled clinical trials.

Southeast Asian Clinical Observations

Research from Malaysia and Thailand — where kratom has a much longer documented history — has provided observational data on kratom use among opioid-dependent individuals. A 2016 study by Singh et al. inDrug and Alcohol Dependencedocumented patterns of kratom use among regular users in Malaysia, including those who transitioned from other opioids to kratom. The researchers found that while kratom dependence did develop in regular users, the severity of kratom withdrawal was generally described as milder than classical opioid withdrawal — though still clinically significant.

Pharmacological Studies

Preclinical research has helped clarify why kratom might affect opioid withdrawal. Studies by Kruegel et al. (2016) inJACS and others have characterized mitragynine as a "G protein-biased" partial agonist at mu-opioid receptors — meaning it activates the receptor through a pathway theoretically associated with less respiratory depression and potentially less physical dependence than full opioid agonists. 7-hydroxymitragynine is a more potent mu-opioid agonist and likely drives the more opioid-like effects at higher doses.

This pharmacological profile provides biological plausibility for kratom's reported effects on opioid withdrawal — but biological plausibility is not clinical evidence.

 

Summary of Research Findings

Evidence Type	What It Found	Strength	Limitations
User surveys (US)	41% used kratom for opioid withdrawal; majority reported effectiveness	Low-moderate	Self-report; no medical verification; selection bias
Systematic reviews	Consistent user reports of withdrawal symptom reduction	Low-moderate	Primarily synthesizes self-report data
Southeast Asian observational studies	Kratom used as opioid substitute; milder withdrawal than classical opioids	Low	Observational; different use context than US
Preclinical pharmacology	Partial mu-opioid agonism provides biological plausibility	Moderate (mechanism)	Animal/lab models; no human clinical outcomes
Randomized controlled trials	None completed for opioid withdrawal indication	N/A	Critical gap in evidence base
FDA approval for OUD	Not approved	N/A	No regulatory validation

 

The Critical Risk: Substituting One Dependence for Another

The most important limitation of kratom as an opioid withdrawal management approach — and one that is frequently underemphasized in user communities — is the real risk of developing kratom dependence in place of opioid dependence.

Kratom's mu-opioid receptor activity means that regular, daily use produces physical dependence. Kratom withdrawal, while generally described as milder than heroin or oxycodone withdrawal, is a real clinical syndrome with documented symptoms:

Some individuals who began using kratom to manage opioid withdrawal have found themselves dependent on kratom — requiring medical assistance to discontinue. This is not a hypothetical risk; it is documented in published case reports and patient data.

The clinical community has described this as a potential "substitution" of dependence rather than resolution of it — an important consideration for anyone evaluating kratom as part of a personal recovery approach. See our detailed article:Is Kratom Addictive?.

 

How Kratom Compares to FDA-Approved OUD Treatments

Factor	Kratom	Buprenorphine (Suboxone)	Methadone
FDA approval for OUD	No	Yes	Yes
Mu-opioid receptor activity	Partial agonist	Partial agonist	Full agonist
Clinical trial evidence	None for OUD	Extensive	Extensive
Dependence risk	Yes — documented	Yes — managed medically	Yes — managed medically
Overdose risk (alone)	Low-moderate	Low	Moderate (requires supervision)
Medical supervision	None (consumer product)	Required (prescription)	Required (licensed clinic)
Standardized dosing	No	Yes	Yes
Drug interaction data	Limited	Well-characterized	Well-characterized
Cost/access	Widely available, low cost	Requires prescription	Requires licensed clinic

 

The Harm Reduction Debate

A legitimate and ongoing debate in the public health and addiction medicine communities concerns whether kratom — despite its risks and lack of FDA approval — might represent a harm reduction option for individuals who cannot or will not access conventional OUD treatment.

Arguments made by harm reduction advocates include:

Arguments against this framing include:

This debate is ongoing in the scientific and policy communities. We present both sides here because our readers deserve to understand the complexity — not because PureCraft CBD takes a position on addiction treatment policy.

 

The FDA and DEA Position

The FDA has been consistent and explicit:kratom is not approved to treat opioid withdrawal, opioid use disorder, or any related condition. The agency has characterized kratom as an opioid with significant abuse potential and has taken enforcement action against kratom vendors making addiction treatment claims.

In 2016, the DEA attempted to emergency-schedule kratom's active alkaloids as Schedule I controlled substances — in part due to concerns about their abuse potential in the context of the opioid crisis. The attempt was withdrawn after significant public and scientific pushback, but the FDA and DEA continue to monitor kratom closely.

PureCraft CBD does not claim that any of our products treat opioid withdrawal or opioid use disorder. View ourpublished lab results for complete product transparency.

 

If You or Someone You Know Is Struggling With Opioid Dependence

Opioid use disorder is a medical condition, not a moral failing. Effective, evidence-based treatments exist and are more accessible than many people realize. Please consider these resources:

 

Frequently Asked Questions

Has kratom been proven to help with opioid withdrawal?

No. There are no completed randomized controlled trials establishing kratom as an effective treatment for opioid withdrawal. The evidence base consists primarily of self-reported user surveys and observational data — which are informative but cannot establish proof of efficacy.

Is kratom FDA-approved for opioid use disorder?

No. The FDA has not approved kratom for opioid use disorder, opioid withdrawal, or any related indication. Kratom is sold as a dietary supplement and has not undergone the clinical trial and regulatory review process required for drug approval.

Why do so many people report that kratom helped their opioid withdrawal?

This is a legitimate observation that the pharmacology supports at a mechanistic level — kratom's partial mu-opioid agonism provides biological plausibility for reducing opioid withdrawal symptoms. Large surveys consistently document this user experience. However, self-reported outcomes cannot establish causation, rule out placebo effects, or confirm that kratom is safer or more effective than evidence-based treatments. User reports are an important signal for researchers, not a substitute for clinical trial evidence.

Is it safer to use kratom for withdrawal than to keep using opioids?

This is a harm reduction question that does not have a simple answer. Kratom carries real risks including its own dependence potential, liver toxicity, and drug interactions. Illicit opioids carry risks of overdose, fentanyl contamination, and infectious disease. Neither choice should be made without medical guidance. FDA-approved treatments (buprenorphine, methadone) have the best evidence profile and should be the first consideration.

Can kratom cause withdrawal itself?

Yes — kratom dependence and withdrawal are clinically documented. Regular kratom use produces physical dependence, and cessation produces a withdrawal syndrome resembling moderate opioid withdrawal. See our full article:Is Kratom Addictive?.

How does kratom compare to buprenorphine for opioid withdrawal?

Buprenorphine is a partial mu-opioid agonist with FDA approval, extensive clinical trial evidence, standardized dosing, medical supervision, and a well-characterized safety profile. Kratom is a partial mu-opioid agonist without FDA approval, no clinical trial evidence for opioid withdrawal, no standardized dosing, no medical supervision, and significant variability in product quality and potency. These are not comparable options in terms of evidence or safety assurance.

What do addiction medicine specialists think about kratom for opioid withdrawal?

The American Society of Addiction Medicine (ASAM) and most addiction medicine specialists do not endorse kratom as a treatment for opioid use disorder. The prevailing position is that FDA-approved medications (buprenorphine, methadone, naltrexone) should be the primary approach, and that individuals seeking help should access medically supervised care rather than self-medicating with unregulated substances.

Could kratom be approved by the FDA for opioid withdrawal in the future?

Theoretically, if kratom's alkaloids underwent rigorous clinical trials demonstrating safety and efficacy for opioid withdrawal, regulatory approval would be possible. Some researchers have called for exactly this kind of research investment. As of the time of writing, no such trials have been completed. Whether the research community pursues this path — and whether findings would support approval — remains to be seen.

Is using kratom for opioid withdrawal legal?

Kratom is federally legal in the United States as of the time of writing, though it is banned in several states (Alabama, Arkansas, Indiana, Rhode Island, Vermont, Wisconsin). Using kratom is not in itself illegal in most of the US — but it is unregulated, and no kratom product is legally marketed as a treatment for opioid use disorder. See our full guide:Is Kratom Legal?.

Can kratom interact with opioid addiction medications?

Yes — this is a critical safety consideration. If someone is taking buprenorphine or methadone, adding kratom creates unpredictable pharmacological interactions. Kratom and buprenorphine both compete at mu-opioid receptors, potentially affecting each other's efficacy and safety. Kratom also inhibits CYP450 enzymes that metabolize methadone, potentially raising methadone blood levels to dangerous concentrations. Never combine kratom with addiction medications without medical supervision.

What is the current state of kratom research for opioid withdrawal?

Researchers are calling for clinical trials but few have been funded or initiated. The National Institute on Drug Abuse (NIDA) has expressed interest in studying kratom's alkaloids as potential OUD treatments, but this work is in early stages. The most needed research is a well-designed, placebo-controlled human clinical trial — which has not yet been conducted.

Does PureCraft CBD recommend kratom for opioid withdrawal?

No. PureCraft CBD does not make any claim that our products treat opioid withdrawal or opioid use disorder. We sell kratom products as general wellness supplements for adult consumers, in compliance with applicable laws. Anyone struggling with opioid dependence should seek medical care — not a supplement retailer.

 

Conclusion

The question of whether kratom can help with opioid withdrawal is one of the most scientifically and ethically complex questions in the kratom landscape. The honest answer based on current evidence: there is a pharmacological rationale and consistent self-reported user data suggesting kratom may reduce opioid withdrawal symptoms — but no completed human clinical trial has validated this, and the risk of substituting one dependence for another is real and documented.

The research is worth taking seriously. The limitations are equally worth taking seriously. And above all, the existence of FDA-approved, evidence-based treatments for opioid use disorder — buprenorphine, methadone, naltrexone — means that kratom should never be framed as a first-line or equivalent option for individuals dealing with opioid dependence.

If you or someone you know is struggling with opioid dependence, please call SAMHSA's National Helpline at 1-800-662-4357. Treatment works, and help is available.

ExplorePureCraft CBD's lab-tested kratom products with complete transparency through ourthird-party lab results. These statements have not been evaluated by the FDA. Our products are not intended to diagnose, treat, cure, or prevent any disease.

 

Sources & Citations

 

Related Articles